MSD hit with €39m fine over contraceptive generic delay
The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Teva breached antitrust rules over Copaxone, says EU
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
Generic maker hits back at Novartis stay bid
HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.
SCOTUS invites govt comment on Teva clash
Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
MSD prevails in diabetes drug dispute with Mylan
MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.
Federal Circuit denies Novartis’ bid to halt generics
Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Swiss pharma company reveals SCOTUS appeal plans
Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big pharma firm settles HIV drug disputes with generic makers
Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.
Generic maker urges review of $235m skinny label decision
A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.
Novartis sued over blockbuster heart failure drug
Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.